Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 16 citing articles:

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 43
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 144, Iss. 7, pp. 714-728
Closed Access | Times Cited: 23
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Alexandra E. Rojek, Benjamin J. McCormick, Joanna Cwykiel, et al.
eJHaem (2024) Vol. 5, Iss. 4, pp. 728-737
Open Access | Times Cited: 5
New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers
Giulia Battaglia, Davide Lazzarotto, Ilaria Tanasi, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 700-700
Open Access
NPM1 Measurable Residual Disease: A Narrative Review
Yadav Chitresh, Shrinidhi Nathany, Krishna Karthik, et al.
Indian Journal of Hematology and Blood Transfusion (2025)
Closed Access
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
Uwe Platzbecker, Richard A. Larson, Sandeep Gurbuxani
HemaSphere (2025) Vol. 9, Iss. 2
Open Access
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1
Evan C. Chen, Shai Shimony, Marlise R. Luskin, et al.
American Journal of Hematology (2025)
Closed Access
Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Keith W. Pratz, Harry P. Erba
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 16-22
Open Access
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Internal Medicine Journal (2025)
Open Access
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Jayastu Senapati, Tapan M. Kadia, Naval Daver, et al.
Cancer (2025) Vol. 131, Iss. 7
Closed Access
Acute myeloid leukemia management and research in 2025
Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, et al.
CA A Cancer Journal for Clinicians (2024)
Open Access | Times Cited: 3
Is Favorable-Risk AML Always Favorable?
Richard Dillon
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, pp. S3-S4
Closed Access
Central nervous system relapse after allogeneic HCT in FLT3-mutated AML
Khouloud Kouidri, Fabian Acker, Rosa Toenges, et al.
Annals of Hematology (2024)
Open Access
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia
Joseph F. Mort, David Brighton, Samantha DiBenedetto, et al.
European Journal Of Haematology (2024)
Open Access
Page 1

Scroll to top